Jump to content

Biochemistry of Alzheimer's disease: Difference between revisions

From Wikipedia, the free encyclopedia
Browse history interactively
← Previous editNext edit →
Content deleted Content added
VisualWikitext
m →‎Glucose consumption: Journal cites, templated 1 journal cites using AWB (10870)
m →‎Glucose consumption: Journal cites, Added 7 dois to journal cites using AWB (10870)
Line 83: Line 83:


==Glucose consumption==
==Glucose consumption==
The human brain is one of the most metabolically active organs in the body and metabolizes a large amount of glucose to produce cellular energy in the form of [[adenosine triphosphate]] (ATP).<ref name=Reference2>{{cite journal | author = Cunnane S, Nugent S, Roy M ''et al.'' | year = 2011 | title = Brain fuel metabolism, aging, and Alzheimer's disease | url = | journal = Nutrition | volume = 27 | issue = 1| pages = 3–20 }}</ref> Despite its high energy demands, the brain is relatively inflexible in its ability to utilize substrates for energy production and relies almost entirely on circulating glucose for its energy needs.<ref name=Reference7>{{cite journal | author = Costantini LC, Barr LJ, Vogel JL, Henderson ST | year = 2008 | title = Hypometabolism as a therapeutic target in Alzheimer's disease | url = | journal = BMC Neurosci | volume = 9 | issue = Suppl 2| page = S16 }}</ref> This dependence on glucose puts the brain at risk if the supply of glucose is interrupted, or if its ability to metabolize glucose becomes defective. If the brain is not able to produce ATP, synapses cannot be maintained and cells cannot function, ultimately leading to impaired cognition.<ref name=Reference7>{{cite journal | author = Costantini LC, Barr LJ, Vogel JL, Henderson ST | year = 2008 | title = Hypometabolism as a therapeutic target in Alzheimer's disease | url = | journal = BMC Neurosci | volume = 9 | issue = Suppl 2| page = S16 }}</ref>
The human brain is one of the most metabolically active organs in the body and metabolizes a large amount of glucose to produce cellular energy in the form of [[adenosine triphosphate]] (ATP).<ref name=Reference2>{{cite journal | author = Cunnane S, Nugent S, Roy M ''et al.'' | year = 2011 | title = Brain fuel metabolism, aging, and Alzheimer's disease | url = | journal = Nutrition | volume = 27 | issue = 1| pages = 3–20 | doi=10.1016/j.nut.2010.07.021}}</ref> Despite its high energy demands, the brain is relatively inflexible in its ability to utilize substrates for energy production and relies almost entirely on circulating glucose for its energy needs.<ref name=Reference7>{{cite journal | author = Costantini LC, Barr LJ, Vogel JL, Henderson ST | year = 2008 | title = Hypometabolism as a therapeutic target in Alzheimer's disease | url = | journal = BMC Neurosci | volume = 9 | issue = Suppl 2| page = S16 | doi=10.1186/1471-2202-9-s2-s16}}</ref> This dependence on glucose puts the brain at risk if the supply of glucose is interrupted, or if its ability to metabolize glucose becomes defective. If the brain is not able to produce ATP, synapses cannot be maintained and cells cannot function, ultimately leading to impaired cognition.<ref name=Reference7>{{cite journal | author = Costantini LC, Barr LJ, Vogel JL, Henderson ST | year = 2008 | title = Hypometabolism as a therapeutic target in Alzheimer's disease | url = | journal = BMC Neurosci | volume = 9 | issue = Suppl 2| page = S16 | doi=10.1186/1471-2202-9-s2-s16}}</ref>


Imaging studies have shown decreased utilization of glucose in the brains of Alzheimer’s disease patients early in the disease, before clinical signs of cognitive impairment occur. This decrease in [[glucose metabolism]] worsens as clinical symptoms develop and the disease progresses.<ref name=Reference8>{{cite journal | author = Hoyer S | year = 1992 | title = Oxidative energy metabolism in Alzheimer brain. Studies in early-onset and late-onset cases | url = | journal = Mol Chem Neuropathol | volume = 16 | issue = 3| pages = 207–224 }}</ref><ref name=Reference9>{{cite journal | author = Small GW, Ercoli LM, Silverman DHS ''et al.'' | year = 2000 | title = Cerebral metabolic and cognitive decline in persons at genetic risk for Alzheimer's disease | url = | journal = Proc Natl Acad Sci U S A | volume = 97 | issue = 11| pages = 6037–6042 }}</ref> Studies have found a 17%-24% decline in cerebral glucose metabolism in patients with Alzheimer’s disease, compared with age-matched controls.<ref name=Reference10>{{cite journal | author = De Leon MJ, Ferris SH, George AE ''et al.'' | year = 1983 | title = Positron emission tomographic studies of aging and Alzheimer disease | url = | journal = Am J Neuroradiol | volume = 4 | issue = 3| pages = 568–571 }}</ref> Numerous imaging studies have since confirmed this observation.
Imaging studies have shown decreased utilization of glucose in the brains of Alzheimer’s disease patients early in the disease, before clinical signs of cognitive impairment occur. This decrease in [[glucose metabolism]] worsens as clinical symptoms develop and the disease progresses.<ref name=Reference8>{{cite journal | author = Hoyer S | year = 1992 | title = Oxidative energy metabolism in Alzheimer brain. Studies in early-onset and late-onset cases | url = | journal = Mol Chem Neuropathol | volume = 16 | issue = 3| pages = 207–224 | doi=10.1007/bf03159971}}</ref><ref name=Reference9>{{cite journal | author = Small GW, Ercoli LM, Silverman DHS ''et al.'' | year = 2000 | title = Cerebral metabolic and cognitive decline in persons at genetic risk for Alzheimer's disease | url = | journal = Proc Natl Acad Sci U S A | volume = 97 | issue = 11| pages = 6037–6042 }}</ref> Studies have found a 17%-24% decline in cerebral glucose metabolism in patients with Alzheimer’s disease, compared with age-matched controls.<ref name=Reference10>{{cite journal | author = De Leon MJ, Ferris SH, George AE ''et al.'' | year = 1983 | title = Positron emission tomographic studies of aging and Alzheimer disease | url = | journal = Am J Neuroradiol | volume = 4 | issue = 3| pages = 568–571 }}</ref> Numerous imaging studies have since confirmed this observation.


Abnormally low rates of cerebral glucose metabolism are found in a characteristic pattern in the Alzheimer’s disease brain, particularly in the posterior cingulate, parietal, temporal, and prefrontal cortices. These brain regions are believed to control multiple aspects of [[memory]] and [[cognition]]. This metabolic pattern is reproducible and has even been proposed as a diagnostic tool for Alzheimer’s disease. Moreover, diminished cerebral glucose metabolism (DCGM) correlates with plaque density and cognitive deficits in patients with more advanced disease.<ref name=Reference10>{{cite journal | author = De Leon MJ, Ferris SH, George AE ''et al.'' | year = 1983 | title = Positron emission tomographic studies of aging and Alzheimer disease | url = | journal = Am J Neuroradiol | volume = 4 | issue = 3| pages = 568–571 }}</ref><ref name=Reference11>{{cite journal | author = Meier-Ruge W, Bertoni-Freddari C, Iwangoff P | year = 1994 | title = Changes in brain glucose metabolism as a key to the pathogenesis of Alzheimer's disease | url = | journal = Gerontology | volume = 40 | issue = 5| pages = 246–252 }}</ref>
Abnormally low rates of cerebral glucose metabolism are found in a characteristic pattern in the Alzheimer’s disease brain, particularly in the posterior cingulate, parietal, temporal, and prefrontal cortices. These brain regions are believed to control multiple aspects of [[memory]] and [[cognition]]. This metabolic pattern is reproducible and has even been proposed as a diagnostic tool for Alzheimer’s disease. Moreover, diminished cerebral glucose metabolism (DCGM) correlates with plaque density and cognitive deficits in patients with more advanced disease.<ref name=Reference10>{{cite journal | author = De Leon MJ, Ferris SH, George AE ''et al.'' | year = 1983 | title = Positron emission tomographic studies of aging and Alzheimer disease | url = | journal = Am J Neuroradiol | volume = 4 | issue = 3| pages = 568–571 }}</ref><ref name=Reference11>{{cite journal | author = Meier-Ruge W, Bertoni-Freddari C, Iwangoff P | year = 1994 | title = Changes in brain glucose metabolism as a key to the pathogenesis of Alzheimer's disease | url = | journal = Gerontology | volume = 40 | issue = 5| pages = 246–252 | doi=10.1159/000213592}}</ref>


Diminished cerebral glucose metabolism (DCGM) may not be solely an artifact of brain cell loss since it occurs in asymptomatic patients at risk for Alzheimer’s disease, such as patients homozygous for the epsilon 4 variant of the [[apolipoprotein E]] gene (APOE4, a genetic risk factor for Alzheimer’s disease), as well as in inherited forms of Alzheimer’s disease.<ref name=Reference4>{{cite journal | author = Reiman EM, Chen K, Alexander GE ''et al.'' | year = 2004 | title = Functional brain abnormalities in young adults at genetic risk for late-onset Alzheimer's dementia | url = | journal = Proc Natl Acad Sci USA | volume = 101 | issue = 1| pages = 284–289 }}</ref> Given that DCGM occurs before other clinical and pathological changes occur, it is unlikely to be due to the gross cell loss observed in Alzheimer’s disease.<ref name=Reference7>{{cite journal | author = Costantini LC, Barr LJ, Vogel JL, Henderson ST | year = 2008 | title = Hypometabolism as a therapeutic target in Alzheimer's disease | url = | journal = BMC Neurosci | volume = 9 | issue = Suppl 2| page = S16 }}</ref>
Diminished cerebral glucose metabolism (DCGM) may not be solely an artifact of brain cell loss since it occurs in asymptomatic patients at risk for Alzheimer’s disease, such as patients homozygous for the epsilon 4 variant of the [[apolipoprotein E]] gene (APOE4, a genetic risk factor for Alzheimer’s disease), as well as in inherited forms of Alzheimer’s disease.<ref name=Reference4>{{cite journal | author = Reiman EM, Chen K, Alexander GE ''et al.'' | year = 2004 | title = Functional brain abnormalities in young adults at genetic risk for late-onset Alzheimer's dementia | url = | journal = Proc Natl Acad Sci USA | volume = 101 | issue = 1| pages = 284–289 }}</ref> Given that DCGM occurs before other clinical and pathological changes occur, it is unlikely to be due to the gross cell loss observed in Alzheimer’s disease.<ref name=Reference7>{{cite journal | author = Costantini LC, Barr LJ, Vogel JL, Henderson ST | year = 2008 | title = Hypometabolism as a therapeutic target in Alzheimer's disease | url = | journal = BMC Neurosci | volume = 9 | issue = Suppl 2| page = S16 | doi=10.1186/1471-2202-9-s2-s16}}</ref>


In imaging studies involving young adult APOE4 carriers, where there were no signs of cognitive impairment, diminished cerebral glucose metabolism (DCGM) was detected in the same areas of the brain as older subjects with Alzheimer’s disease.<ref name=Reference4>{{cite journal | author = Reiman EM, Chen K, Alexander GE ''et al.'' | year = 2004 | title = Functional brain abnormalities in young adults at genetic risk for late-onset Alzheimer's dementia | url = | journal = Proc Natl Acad Sci USA | volume = 101 | issue = 1| pages = 284–289 }}</ref> However, DCGM is not exclusive to APOE4 carriers. By the time Alzheimer’s has been diagnosed, DCGM occurs in genotypes APOE3/E4, APOE3/E3, and APOE4/E4.<ref name=Reference12>{{cite journal | author = Corder EH, Jelic V, Basun H ''et al.'' | year = 1997 | title = No difference in cerebral glucose metabolism in patients with Alzheimer disease and differing apolipoprotein E genotypes | url = | journal = Arch Neurol | volume = 54 | issue = 3| pages = 273–277 }}</ref> Thus, DCGM is a metabolic [[biomarker]] for the disease state.<ref>{{cite news|url=http://www.about-axona.com/assets/files/us-en/hcp/pdf/KAXO1056_DCGM_Adv_NR_MV01a.pdf|accessdate=9 October 2013}}</ref>
In imaging studies involving young adult APOE4 carriers, where there were no signs of cognitive impairment, diminished cerebral glucose metabolism (DCGM) was detected in the same areas of the brain as older subjects with Alzheimer’s disease.<ref name=Reference4>{{cite journal | author = Reiman EM, Chen K, Alexander GE ''et al.'' | year = 2004 | title = Functional brain abnormalities in young adults at genetic risk for late-onset Alzheimer's dementia | url = | journal = Proc Natl Acad Sci USA | volume = 101 | issue = 1| pages = 284–289 }}</ref> However, DCGM is not exclusive to APOE4 carriers. By the time Alzheimer’s has been diagnosed, DCGM occurs in genotypes APOE3/E4, APOE3/E3, and APOE4/E4.<ref name=Reference12>{{cite journal | author = Corder EH, Jelic V, Basun H ''et al.'' | year = 1997 | title = No difference in cerebral glucose metabolism in patients with Alzheimer disease and differing apolipoprotein E genotypes | url = | journal = Arch Neurol | volume = 54 | issue = 3| pages = 273–277 | doi=10.1001/archneur.1997.00550150035013}}</ref> Thus, DCGM is a metabolic [[biomarker]] for the disease state.<ref>{{cite news|url=http://www.about-axona.com/assets/files/us-en/hcp/pdf/KAXO1056_DCGM_Adv_NR_MV01a.pdf|accessdate=9 October 2013}}</ref>


==References==
==References==

Revision as of 11:18, 17 April 2015

Illustration depicting neuronal degeneration associated with Alzheimer's Disease

The biochemistry of Alzheimer's disease (AD), one of the most common causes of adult dementia, is as yet not well understood. AD has been identified as a protein misfolding disease due to the accumulation of abnormally folded amyloid beta protein in the brains of Alzheimer's patients.[1] Amyloid beta, also written Aβ, is a short peptide that is an abnormal proteolytic byproduct of the transmembrane protein amyloid precursor protein (APP), whose function is unclear but thought to be involved in neuronal development.[2] The presenilins are components of proteolytic complex involved in APP processing and degradation.[3]

Amyloid beta monomers are soluble and contain short regions of beta sheet and polyproline II helix secondary structures in solution,[4] though they are largely alpha helical in membranes;[5] however, at sufficiently high concentration, they undergo a dramatic conformational change to form a beta sheet-rich tertiary structure that aggregates to form amyloid fibrils.[6] These fibrils deposit outside neurons in dense formations known as senile plaques or neuritic plaques, in less dense aggregates as diffuse plaques, and sometimes in the walls of small blood vessels in the brain in a process called amyloid angiopathy or congophilic angiopathy.

AD is also considered a tauopathy due to abnormal aggregation of the tau protein, a microtubule-associated protein expressed in neurons that normally acts to stabilize microtubules in the cell cytoskeleton. Like most microtubule-associated proteins, tau is normally regulated by phosphorylation; however, in AD patients, hyperphosphorylated tau accumulates as paired helical filaments[7] that in turn aggregate into masses inside nerve cell bodies known as neurofibrillary tangles and as dystrophic neurites associated with amyloid plaques. Although little is known about the process of filament assembly, it has recently been shown that a depletion of a prolyl isomerase protein in the parvulin family accelerates the accumulation of abnormal tau.[8][9]

Neuroinflammation is also involved in the complex cascade leading to AD pathology and symptoms. Considerable pathological and clinical evidence documents immunological changes associated with AD, including increased pro-inflammatory cytokine concentrations in the blood and cerebrospinal fluid.[10][11] Whether these changes may be a cause or consequence of AD remains to be fully understood, but inflammation within the brain, including increased reactivity of the resident microglia towards amyloid deposits, has been implicated in the pathogenesis and progression of AD.

Neuropathology

At a macroscopic level, AD is characterized by loss of neurons and synapses in the cerebral cortex and certain subcortical regions. This results in gross atrophy of the affected regions, including degeneration in the temporal lobe and parietal lobe, and parts of the frontal cortex and cingulate gyrus.[12]

Both amyloid plaques and neurofibrillary tangles are clearly visible by microscopy in AD brains.[13] Plaques are dense, mostly insoluble deposits of protein and cellular material outside and around neurons. Tangles are insoluble twisted fibers that build up inside the nerve cell. Though many older people develop some plaques and tangles, the brains of AD patients have them to a much greater extent and in different brain locations.[14]

Biochemical characteristics

Alzheimer's disease has been identified as a protein misfolding disease, or proteopathy, due to the accumulation of abnormally folded Amyloid-beta proteins in the brains of AD patients.[1] Although AD shares pathophysiological mechanisms with prion diseases, it should be noted that AD is not transmissible like prion diseases.[15] Amyloid-beta, also written Aβ, is a short peptide that is a proteolytic byproduct of the transmembrane protein amyloid precursor protein (APP), whose function is unclear but thought to be involved in neuronal development. The presenilins are components of a proteolytic complex involved in APP processing and degradation.[3] Although amyloid beta monomers are harmless, they undergo a dramatic conformational change at sufficiently high concentration to form a beta sheet-rich tertiary structure that aggregates to form amyloid fibrils[6] that deposit outside neurons in dense formations known as senile plaques or neuritic plaques, in less dense aggregates as diffuse plaques, and sometimes in the walls of small blood vessels in the brain in a process called amyloid angiopathy or congophilic angiopathy.

AD is also considered a tauopathy due to abnormal aggregation of the tau protein, a microtubule-associated protein expressed in neurons that normally acts to stabilize microtubules in the cell cytoskeleton. Like most microtubule-associated proteins, tau is normally regulated by phosphorylation; however, in AD patients, hyperphosphorylated tau accumulates as paired helical filaments[7] that in turn aggregate into masses inside nerve cell bodies known as neurofibrillary tangles and as dystrophic neurites associated with amyloid plaques.

Levels of the neurotransmitter acetylcholine are reduced. Levels of the neurotransmitters serotonin, norepinephrine, and somatostatin are also often reduced. Glutamate levels are usually elevated.[16]

Disease mechanism

Although the gross histological features of AD in the brain are well characterized, three major hypotheses have been advanced regarding the primary cause. The oldest hypothesis suggests that deficiency in cholinergic signaling initiates the progression of the disease. Two alternative misfolding hypotheses instead suggest that either tau protein or amyloid beta initiates the cascade. While researchers have not identified a clear causative pathway originating from any of the three molecular hypotheses to explain the gross anatomical changes observed in advanced AD, variants of the amyloid beta hypothesis of molecular initiation have become dominant among the three possibilities.

Cholinergic hypothesis

The oldest hypothesis is the "cholinergic hypothesis". It states that Alzheimer's begins as a deficiency in the production of acetylcholine, a vital neurotransmitter. Much early therapeutic research was based on this hypothesis, including restoration of the "cholinergic nuclei". The possibility of cell-replacement therapy was investigated on the basis of this hypothesis. All of the first-generation anti-Alzheimer's medications are based on this hypothesis and work to preserve acetylcholine by inhibiting acetylcholinesterases (enzymes that break down acetylcholine). These medications, though sometimes beneficial, have not led to a cure. In all cases, they have served to only treat symptoms of the disease and have neither halted nor reversed it. These results and other research have led to the conclusion that acetylcholine deficiencies may not be directly causal, but are a result of widespread brain tissue damage, damage so widespread that cell-replacement therapies are likely to be impractical. More recently, cholinergic effects have been proposed as a potential causative agent for the formation of plaques and tangles[17] leading to generalized neuroinflammation.[18]

More recent hypotheses center on the effects of the misfolded and aggregated proteins, amyloid beta and tau. The two positions are lightheartedly described as "ba-ptist" and "tau-ist" viewpoints in one scientific publication. Therein, it is suggested that "Tau-ists" believe that the tau protein abnormalities initiate the disease cascade, while "ba-ptists" believe that beta amyloid deposits are the causative factor in the disease.[19]

Tau hypothesis

The hypothesis that tau is the primary causative factor has long been grounded in the observation that deposition of amyloid plaques does not correlate well with neuron loss.[20] A mechanism for neurotoxicity has been proposed based on the loss of microtubule-stabilizing tau protein that leads to the degradation of the cytoskeleton.[21] However, consensus has not been reached on whether tau hyperphosphorylation precedes or is caused by the formation of the abnormal helical filament aggregates.[19] Support for the tau hypothesis also derives from the existence of other diseases known as tauopathies in which the same protein is identifiably misfolded.[22] However, a majority of researchers support the alternative hypothesis that amyloid is the primary causative agent.[19]

Amyloid hypothesis

The amyloid hypothesis is initially compelling because the gene for the amyloid beta precursor APP is located on chromosome 21, and patients with trisomy 21 - better known as Down syndrome - who thus have an extra gene copy almost universally exhibit AD-like disorders by 40 years of age.[23][24] The traditional formulation of the amyloid hypothesis points to the cytotoxicity of mature aggregated amyloid fibrils, which are believed to be the toxic form of the protein responsible for disrupting the cell's calcium ion homeostasis and thus inducing apoptosis.[25] This hypothesis is supported by the observation that higher levels of a variant of the beta amyloid protein known to form fibrils faster in vitro correlate with earlier onset and greater cognitive impairment in mouse models[26] and with AD diagnosis in humans.[27] However, mechanisms for the induced calcium influx, or proposals for alternative cytotoxic mechanisms, by mature fibrils are not obvious.

A more recent and broadly supported variation of the amyloid hypothesis identifies the cytotoxic species as an intermediate misfolded form of amyloid beta, neither a soluble monomer nor a mature aggregated polymer but an oligomeric species, possibly toroidal or star-shaped with a central channel[28] that may induce apoptosis by physically piercing the cell membrane.[29] A related alternative suggests that a globular oligomer localized to dendritic processes and axons in neurons is the cytotoxic species.[30][31]

Relevantly, the cytotoxic-fibril hypothesis presented a clear target for drug development: inhibit the fibrillization process. Much early development work on lead compounds has focused on this inhibition;[32][33][34] most are also reported to reduce neurotoxicity, but the toxic-oligomer theory would imply that prevention of oligomeric assembly is the more important process[35] or that a better target lies upstream, for example in the inhibition of APP processing to amyloid beta.[36]

Soluble intracellular (o)Aβ42

Two research papers published in 2009 have shown that oligomeric (o)Aβ42 (specific toxic species of Aβ), when in soluble intracellular form, acutely inhibit synaptic transmission, a pathophysiology that characterizes AD (especially in early stages), by activating casein kinase 2.[37][38]

Isoprenoid changes

A 1994 study [39] showed that the isoprenoid changes in Alzheimer's disease differ from those occurring during normal aging and that this disease cannot, therefore, be regarded as a result of premature aging. During aging the human brain shows a progressive increase in levels of dolichol, a reduction in levels of ubiquinone, but relatively unchanged concentrations of cholesterol and dolichyl phosphate. In Alzheimer's disease, the situation is reversed with decreased levels of dolichol and increased levels of ubiquinone. The concentrations of dolichyl phosphate are also increased, while cholesterol remains unchanged. The increase in the sugar carrier dolichyl phosphate may reflect an increased rate of glycosylation in the diseased brain and the increase in the endogenous anti-oxidant ubiquinone an attempt to protect the brain from oxidative stress, for instance induced by lipid peroxidation.[40] These findings appear to have been supported by a trial conducted at the Brain Sciences Institute at Swinburne University in Melbourne, Australia, reported in 2006, that confirmed certain neurocognitive effects of the polyprenol preparation Ropren identified previously in Russia [41] (polyprenols are metabolised into dolichols in the body).

Glucose consumption

The human brain is one of the most metabolically active organs in the body and metabolizes a large amount of glucose to produce cellular energy in the form of adenosine triphosphate (ATP).[42] Despite its high energy demands, the brain is relatively inflexible in its ability to utilize substrates for energy production and relies almost entirely on circulating glucose for its energy needs.[43] This dependence on glucose puts the brain at risk if the supply of glucose is interrupted, or if its ability to metabolize glucose becomes defective. If the brain is not able to produce ATP, synapses cannot be maintained and cells cannot function, ultimately leading to impaired cognition.[43]

Imaging studies have shown decreased utilization of glucose in the brains of Alzheimer’s disease patients early in the disease, before clinical signs of cognitive impairment occur. This decrease in glucose metabolism worsens as clinical symptoms develop and the disease progresses.[44][45] Studies have found a 17%-24% decline in cerebral glucose metabolism in patients with Alzheimer’s disease, compared with age-matched controls.[46] Numerous imaging studies have since confirmed this observation.

Abnormally low rates of cerebral glucose metabolism are found in a characteristic pattern in the Alzheimer’s disease brain, particularly in the posterior cingulate, parietal, temporal, and prefrontal cortices. These brain regions are believed to control multiple aspects of memory and cognition. This metabolic pattern is reproducible and has even been proposed as a diagnostic tool for Alzheimer’s disease. Moreover, diminished cerebral glucose metabolism (DCGM) correlates with plaque density and cognitive deficits in patients with more advanced disease.[46][47]

Diminished cerebral glucose metabolism (DCGM) may not be solely an artifact of brain cell loss since it occurs in asymptomatic patients at risk for Alzheimer’s disease, such as patients homozygous for the epsilon 4 variant of the apolipoprotein E gene (APOE4, a genetic risk factor for Alzheimer’s disease), as well as in inherited forms of Alzheimer’s disease.[48] Given that DCGM occurs before other clinical and pathological changes occur, it is unlikely to be due to the gross cell loss observed in Alzheimer’s disease.[43]

In imaging studies involving young adult APOE4 carriers, where there were no signs of cognitive impairment, diminished cerebral glucose metabolism (DCGM) was detected in the same areas of the brain as older subjects with Alzheimer’s disease.[48] However, DCGM is not exclusive to APOE4 carriers. By the time Alzheimer’s has been diagnosed, DCGM occurs in genotypes APOE3/E4, APOE3/E3, and APOE4/E4.[49] Thus, DCGM is a metabolic biomarker for the disease state.[50]

References

  1. ^ a b Hashimoto M, Rockenstein E, Crews L, Masliah E (2003). "Role of protein aggregation in mitochondrial dysfunction and neurodegeneration in Alzheimer's and Parkinson's diseases". Neuromolecular Med. 4 (1–2): 21–36. doi:10.1385/NMM:4:1-2:21. PMID 14528050.{{cite journal}}: CS1 maint: multiple names: authors list (link) Cite error: The named reference "Hashimoto" was defined multiple times with different content (see the help page).
  2. ^ Kerr ML, Small DH (2005). "Cytoplasmic domain of the beta-amyloid protein precursor of Alzheimer's disease: function, regulation of proteolysis, and implications for drug development". J. Neurosci. Res. 80 (2): 151–9. doi:10.1002/jnr.20408. PMID 15672415.
  3. ^ a b Cai D, Netzer WJ, Zhong M; Netzer; Zhong; Lin; Du; Frohman; Foster; Sisodia; Xu; Gorelick; Greengard; et al. (2006). "Presenilin-1 uses phospholipase D1 as a negative regulator of beta-amyloid formation". Proc. Natl. Acad. Sci. U.S.A. 103 (6): 1941–6. Bibcode:2006PNAS..103.1941C. doi:10.1073/pnas.0510708103. PMC 1413665. PMID 16449386. {{cite journal}}: Explicit use of et al. in: |author= (help)CS1 maint: multiple names: authors list (link) Cite error: The named reference "Cai" was defined multiple times with different content (see the help page).
  4. ^ Danielsson J, Andersson A, Jarvet J, Gräslund A (2006). "15N relaxation study of the amyloid beta-peptide: structural propensities and persistence length". Magnetic resonance in chemistry : MRC. 44 Spec No: S114–21. doi:10.1002/mrc.1814. PMID 16826550.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  5. ^ Tomaselli S, Esposito V, Vangone P; et al. (2006). "The alpha-to-beta conformational transition of Alzheimer's Abeta-(1-42) peptide in aqueous media is reversible: a step by step conformational analysis suggests the location of beta conformation seeding". Chembiochem. 7 (2): 257–67. doi:10.1002/cbic.200500223. PMID 16444756. {{cite journal}}: Explicit use of et al. in: |author= (help)CS1 maint: multiple names: authors list (link)
  6. ^ a b Ohnishi S, Takano K (2004). "Amyloid fibrils from the viewpoint of protein folding". Cell. Mol. Life Sci. 61 (5): 511–24. doi:10.1007/s00018-003-3264-8. PMID 15004691. Cite error: The named reference "Ohnishi" was defined multiple times with different content (see the help page).
  7. ^ a b Goedert M, Klug A, Crowther RA (2006). "Tau protein, the paired helical filament and Alzheimer's disease". J. Alzheimers Dis. 9 (3 Suppl): 195–207. PMID 16914859.{{cite journal}}: CS1 maint: multiple names: authors list (link) Cite error: The named reference "Goedert" was defined multiple times with different content (see the help page).
  8. ^ Pastorino L, Sun A, Lu PJ; Sun; Lu; Zhou; Balastik; Finn; Wulf; Lim; Li; Li; Xia; Nicholson; Lu; et al. (2006). "The prolyl isomerase Pin1 regulates amyloid precursor protein processing and amyloid-beta production". Nature. 440 (7083): 528–34. Bibcode:2006Natur.440..528P. doi:10.1038/nature04543. PMID 16554819. {{cite journal}}: Explicit use of et al. in: |author= (help)CS1 maint: multiple names: authors list (link)
  9. ^ Lim J, Lu KP (2005). "Pinning down phosphorylated tau and tauopathies". Biochim. Biophys. Acta. 1739 (2–3): 311–22. doi:10.1016/j.bbadis.2004.10.003. PMID 15615648.
  10. ^ Akiyama H,Barger S,Barnum S,Bradt B,Bauer J, Cole GM; et al. (2000). "Inflammation and Alzheimer's disease". Neurobiol Aging. 21 (3): 383–421. doi:10.1016/S0197-4580(00)00124-X. PMID 10858586. {{cite journal}}: Explicit use of et al. in: |author= (help)CS1 maint: multiple names: authors list (link)
  11. ^ Swardfager W, Lanctôt K, Rothenburg L, Wong A, Cappell J, Herrmann N (2010). "A meta-analysis of cytokines in Alzheimer's disease". Biol Psychiat. 68 (10): 930–941. doi:10.1016/j.biopsych.2010.06.012. PMID 20692646.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  12. ^ Wenk GL (2003). "Neuropathologic changes in Alzheimer's disease". J Clin Psychiatry. 64 Suppl 9: 7–10. PMID 12934968.
  13. ^ Tiraboschi P, Hansen L, Thal L, Corey-Bloom J (2004). "The importance of neuritic plaques and tangles to the development and evolution of AD". Neurology. 62 (11): 1984–9. doi:10.1212/01.WNL.0000129697.01779.0A. PMID 15184601.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  14. ^ Bouras C, Hof PR, Giannakopoulos P, Michel JP, Morrison JH (1994). "Regional distribution of neurofibrillary tangles and senile plaques in the cerebral cortex of elderly patients: a quantitative evaluation of a one-year autopsy population from a geriatric hospital". Cereb. Cortex. 4 (2): 138–50. doi:10.1093/cercor/4.2.138. PMID 8038565.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  15. ^ Castellni RJ, Perry G, Smith MA (2004). "Prion disease and Alzheimer's disease: pathogenic overlap". PubMed. 64: 11–7. PMID 15190676.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  16. ^ Baskys. "Receptor found that could lead to better treatments for stroke, alzheimer's disease". UCI Medical Center. Retrieved 2006-11-04.
  17. ^ Shen ZX (2004). "Brain cholinesterases: II. The molecular and cellular basis of Alzheimer's disease". Med. Hypotheses. 63 (2): 308–21. doi:10.1016/j.mehy.2004.02.031. PMID 15236795.
  18. ^ Wenk GL (2003). "Neuropathologic changes in Alzheimer's disease". The Journal of clinical psychiatry. 64 Suppl 9: 7–10. PMID 12934968.
  19. ^ a b c Mudher A, Lovestone S (2002). "Alzheimer's disease-do tauists and baptists finally shake hands?". Trends Neurosci. 25 (1): 22–6. doi:10.1016/S0166-2236(00)02031-2. PMID 11801334.
  20. ^ Schmitz C, Rutten BP, Pielen A; et al. (1 April 2004). "Hippocampal neuron loss exceeds amyloid plaque load in a transgenic mouse model of Alzheimer's disease". Am. J. Pathol. 164 (4): 1495–502. doi:10.1016/S0002-9440(10)63235-X. PMC 1615337. PMID 15039236. {{cite journal}}: Explicit use of et al. in: |author= (help)CS1 maint: multiple names: authors list (link)
  21. ^ Gray EG, Paula-Barbosa M, Roher A (1987). "Alzheimer's disease: paired helical filaments and cytomembranes". Neuropathol. Appl. Neurobiol. 13 (2): 91–110. doi:10.1111/j.1365-2990.1987.tb00174.x. PMID 3614544.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  22. ^ Williams DR (2006). "Tauopathies: classification and clinical update on neurodegenerative diseases associated with microtubule-associated protein tau". Internal medicine journal. 36 (10): 652–60. doi:10.1111/j.1445-5994.2006.01153.x. PMID 16958643.
  23. ^ Nistor M, Don M, Parekh M; et al. (2007). "Alpha- and beta-secretase activity as a function of age and beta-amyloid in Down syndrome and normal brain". Neurobiol. Aging. 28 (10): 1493–506. doi:10.1016/j.neurobiolaging.2006.06.023. PMC 3375834. PMID 16904243. {{cite journal}}: Explicit use of et al. in: |author= (help)CS1 maint: multiple names: authors list (link)
  24. ^ Lott IT, Head E (2005). "Alzheimer disease and Down syndrome: factors in pathogenesis". Neurobiol. Aging. 26 (3): 383–9. doi:10.1016/j.neurobiolaging.2004.08.005. PMID 15639317.
  25. ^ Yankner BA, Duffy LK, Kirschner DA; Duffy; Kirschner (1990). "Neurotrophic and neurotoxic effects of amyloid beta protein: reversal by tachykinin neuropeptides". Science. 250 (4978): 279–82. Bibcode:1990Sci...250..279Y. doi:10.1126/science.2218531. PMID 2218531.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  26. ^ Iijima K, Liu HP, Chiang AS, Hearn SA, Konsolaki M, Zhong Y; Liu; Chiang; Hearn; Konsolaki; Zhong (2004). "Dissecting the pathological effects of human Abeta40 and Abeta42 in Drosophila: a potential model for Alzheimer's disease". Proc. Natl. Acad. Sci. U.S.A. 101 (17): 6623–8. Bibcode:2004PNAS..101.6623I. doi:10.1073/pnas.0400895101. PMC 404095. PMID 15069204.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  27. ^ Gregory GC, Halliday GM (2005). "What is the dominant Abeta species in human brain tissue? A review". Neurotoxicity research. 7 (1–2): 29–41. doi:10.1007/BF03033774. PMID 15639796.
  28. ^ Blanchard BJ, Hiniker AE, Lu CC, Margolin Y, Yu AS, Ingram VM (2000). "Elimination of Amyloid beta Neurotoxicity". J Alzheimers Dis. 2 (2): 137–149. PMID 12214104.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  29. ^ Abramov AY, Canevari L, Duchen MR (2004). "Calcium signals induced by amyloid beta peptide and their consequences in neurons and astrocytes in culture". Biochim. Biophys. Acta. 1742 (1–3): 81–7. doi:10.1016/j.bbamcr.2004.09.006. PMID 15590058.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  30. ^ Barghorn S, Nimmrich V, Striebinger A; et al. (2005). "Globular amyloid beta-peptide oligomer - a homogenous and stable neuropathological protein in Alzheimer's disease". J. Neurochem. 95 (3): 834–47. doi:10.1111/j.1471-4159.2005.03407.x. PMID 16135089. {{cite journal}}: Explicit use of et al. in: |author= (help)CS1 maint: multiple names: authors list (link)
  31. ^ Kokubo H, Kayed R, Glabe CG, Yamaguchi H (2005). "Soluble Abeta oligomers ultrastructurally localize to cell processes and might be related to synaptic dysfunction in Alzheimer's disease brain". Brain Res. 1031 (2): 222–8. doi:10.1016/j.brainres.2004.10.041. PMID 15649447.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  32. ^ Blanchard BJ, Chen A, Rozeboom LM, Stafford KA, Weigele P, Ingram VM; Chen; Rozeboom; Stafford; Weigele; Ingram (2004). "Efficient reversal of Alzheimer's disease fibril formation and elimination of neurotoxicity by a small molecule". Proc. Natl. Acad. Sci. U.S.A. 101 (40): 14326–32. Bibcode:2004PNAS..10114326B. doi:10.1073/pnas.0405941101. PMC 521943. PMID 15388848.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  33. ^ Porat Y, Abramowitz A, Gazit E (2006). "Inhibition of amyloid fibril formation by polyphenols: structural similarity and aromatic interactions as a common inhibition mechanism". Chem Biol Drug Des. 67 (1): 27–37. doi:10.1111/j.1747-0285.2005.00318.x. PMID 16492146.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  34. ^ Kanapathipillai M, Lentzen G, Sierks M, Park CB (2005). "Ectoine and hydroxyectoine inhibit aggregation and neurotoxicity of Alzheimer's beta-amyloid". FEBS Lett. 579 (21): 4775–80. doi:10.1016/j.febslet.2005.07.057. PMID 16098972.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  35. ^ Lee KH, Shin BH, Shin KJ, Kim DJ, Yu J (2005). "A hybrid molecule that prohibits amyloid fibrils and alleviates neuronal toxicity induced by beta-amyloid (1-42)". Biochem. Biophys. Res. Commun. 328 (4): 816–23. doi:10.1016/j.bbrc.2005.01.030. PMID 15707952.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  36. ^ Espeseth AS, Xu M, Huang Q; et al. (2005). "Compounds that bind APP and inhibit Abeta processing in vitro suggest a novel approach to Alzheimer disease therapeutics". J. Biol. Chem. 280 (18): 17792–7. doi:10.1074/jbc.M414331200. PMID 15737955. {{cite journal}}: Explicit use of et al. in: |author= (help)CS1 maint: multiple names: authors list (link) CS1 maint: unflagged free DOI (link)
  37. ^ Attention: This template ({{cite doi}}) is deprecated. To cite the publication identified by doi:10.1073/pnas.0900944106, please use {{cite journal}} (if it was published in a bona fide academic journal, otherwise {{cite report}} with |doi=10.1073/pnas.0900944106 instead.
  38. ^ Attention: This template ({{cite doi}}) is deprecated. To cite the publication identified by doi:10.1073/pnas.0901229106, please use {{cite journal}} (if it was published in a bona fide academic journal, otherwise {{cite report}} with |doi=10.1073/pnas.0901229106 instead.
  39. ^ Edlund, C; Söderberg, M; Kristensson, K (1994). "Isoprenoids in aging and neurodegeneration". Neurochemistry international. 25 (1): 35–8. doi:10.1016/0197-0186(94)90050-7. PMID 7950967.
  40. ^ Edlund C, Söderberg M, Kristensson K (July 1994). "Isoprenoids in aging and neurodegeneration". Neurochem Int. 25 (1): 35–8. doi:10.1016/0197-0186(94)90050-7. PMID 7950967.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  41. ^ Sviderskii, VL; Khovanskikh, AE; Rozengart, EV; Moralev, SN; Yagodina, OV; Gorelkin, VS; Basova, IN; Kormilitsyn, BN; Nikitina, TV; Roshchin, V. I.; Sultanov, V. S. (2006). "A comparative study of the effect of the polyprenol preparation ropren from coniferous plants on the key enzymes of the cholinergic and monoaminergic types of nervous transmission". Doklady. Biochemistry and biophysics (in Russian). 408: 148–51. doi:10.1134/S1607672906030112. PMID 16913416. {{cite journal}}: Unknown parameter |laysummary= ignored (help)[verification needed]
  42. ^ Cunnane S, Nugent S, Roy M; et al. (2011). "Brain fuel metabolism, aging, and Alzheimer's disease". Nutrition. 27 (1): 3–20. doi:10.1016/j.nut.2010.07.021. {{cite journal}}: Explicit use of et al. in: |author= (help)CS1 maint: multiple names: authors list (link)
  43. ^ a b c Costantini LC, Barr LJ, Vogel JL, Henderson ST (2008). "Hypometabolism as a therapeutic target in Alzheimer's disease". BMC Neurosci. 9 (Suppl 2): S16. doi:10.1186/1471-2202-9-s2-s16.{{cite journal}}: CS1 maint: multiple names: authors list (link) CS1 maint: unflagged free DOI (link)
  44. ^ Hoyer S (1992). "Oxidative energy metabolism in Alzheimer brain. Studies in early-onset and late-onset cases". Mol Chem Neuropathol. 16 (3): 207–224. doi:10.1007/bf03159971.
  45. ^ Small GW, Ercoli LM, Silverman DHS; et al. (2000). "Cerebral metabolic and cognitive decline in persons at genetic risk for Alzheimer's disease". Proc Natl Acad Sci U S A. 97 (11): 6037–6042. {{cite journal}}: Explicit use of et al. in: |author= (help)CS1 maint: multiple names: authors list (link)
  46. ^ a b De Leon MJ, Ferris SH, George AE; et al. (1983). "Positron emission tomographic studies of aging and Alzheimer disease". Am J Neuroradiol. 4 (3): 568–571. {{cite journal}}: Explicit use of et al. in: |author= (help)CS1 maint: multiple names: authors list (link)
  47. ^ Meier-Ruge W, Bertoni-Freddari C, Iwangoff P (1994). "Changes in brain glucose metabolism as a key to the pathogenesis of Alzheimer's disease". Gerontology. 40 (5): 246–252. doi:10.1159/000213592.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  48. ^ a b Reiman EM, Chen K, Alexander GE; et al. (2004). "Functional brain abnormalities in young adults at genetic risk for late-onset Alzheimer's dementia". Proc Natl Acad Sci USA. 101 (1): 284–289. {{cite journal}}: Explicit use of et al. in: |author= (help)CS1 maint: multiple names: authors list (link)
  49. ^ Corder EH, Jelic V, Basun H; et al. (1997). "No difference in cerebral glucose metabolism in patients with Alzheimer disease and differing apolipoprotein E genotypes". Arch Neurol. 54 (3): 273–277. doi:10.1001/archneur.1997.00550150035013. {{cite journal}}: Explicit use of et al. in: |author= (help)CS1 maint: multiple names: authors list (link)
  50. ^ http://www.about-axona.com/assets/files/us-en/hcp/pdf/KAXO1056_DCGM_Adv_NR_MV01a.pdf. Retrieved 9 October 2013. {{cite news}}: Missing or empty |title= (help)
Retrieved from "https://en.wikipedia.org/w/index.php?title=Biochemistry_of_Alzheimer%27s_disease&oldid=656885912"